Please assess the completion status of the following clinical trial:

Trial Title: Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients must meet all the following inclusion criteria to be eligible for the study.~1. Written informed consent before any study-related procedure.~2. Adults and children:~   1. Adults 18 to 75 (65) years old with AML or MM.~  2. Children 1 to 17 years old with AML, only in Phase IIa.~3. Confirmed diagnosis of AML or MM as follows:~   1. AML: Primary or secondary AML (any subtype except acute promyelocytic leukemia) according to World Health Organization (WHO) classification.~  2. MM with measurable disease as defined by the International Myeloma Working Group (IMWG).~4. Patients with relapse or refractory disease:~   1. AML patients must be unlikely to benefit from cytotoxic chemotherapy as follows:~      * Leukemia refractory to at least 2 induction attempts.~     * Leukemia in relapse within 1 year following complete response (CR) after at least 2 induction attempts.~     * High-risk leukemia in adults according to 2017 European LeukemiaNet (ELN) in first relapse after a hypomethylating agent or a cycle containing cytarabine at a dose ≥ 1g/sqm a day (e.g. FLAG-IDA), except for FLT3-mutated AML.~     * High-risk leukemia in children as defined by the Italian Association of Pediatric Hematology and Oncology (AIEOP).~  2. Patients with MM must have a relapse or refractory disease after at least 4 different prior treatments in 3 treatment lines, or 4 treatments in 2 treatment lines in case of early relapsing patients (relapse in less than 1.5 years). Treatments include:~      * Proteasome inhibitor~     * High-dose alkylating agent if patients less than 70 years old~     * Immunomodulatory drug (IMID)~     * A monoclonal antibody (i.e. anti CD38 monoclonal antibody)~5. Positive CD44v6 expression on tumor cells by flow cytometry.~6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.~7. Life expectancy of at least 12 weeks.~8. Adequate organ function (hepatic, cardiac, pulmonary).~9. Recovery from toxicities of clinical consequence attributed to previous chemotherapy to CTCAE v5.0 Grade 1 (i.e., certain toxicities such as alopecia will not be considered in this category).~10. Ability to comply with study procedures, including hospitalization and protocol-specified acquisition of blood and/or bone marrow specimens.~11. Willing to be followed up long term, i.e. a 15-year follow up as required by health authorities for cell and gene therapy products.~12. Women of childbearing potential must test negative for pregnancy at enrolment and during the study.~Exclusion Criteria:~At screening: patients must meet none of the following exclusion criteria to be eligible for the study:~1. History of or candidate for allogeneic stem cell transplantation.~2. Cardiovascular, pulmonary, renal, and hepatic functions that in the judgment of the investigator are insufficient for the patient to undergo investigational CAR T-cell therapy.~3. Any history of or suspected current autoimmune disorders (apart from vitiligo, resolved childhood atopic dermatitis, Graves' disease clinically controlled).~4. History of rheumatologic disorders requiring specific treatment at any time in the patient's medical history.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- MLM-CAR44.1 T-cells infusion (Type: EXPERIMENTAL): PHASE I: i.v. single dose of MLM-CAR44.1 T-cells: 0.5 x 10E6/Kg or 1 x 10E6/Kg or 2 x10E6/Kg according to the BOIN design.~PHASE IIa: i.v. single dose of MLM-CAR44.1 T-cells corresponding to the maximum tolerated dose (MTD).~Phase I and IIa Pre-treatment: lymphodepleting chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) daily from day -5 to day -3

Based on this trial design, predict the completion outcome and termination type (if applicable).